Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Loperamide

Classification: B

Drug products: Dimor®, Imodium, Imodium Janssen-Cilag Ltd, Imodium N, Imodium®, Imolopera, Lopacut, Loperamid ABECE, Loperamid Apofri, Loperamid Evolan, Loperamid Mylan

ATC code: A07DA03

Substances: loperamide, loperamide hydrochloride, loperamide oxide, loperamide oxide monohydrate

Summary

Controlled studies of differences between men and women are lacking for efficacy, safety, and pharmacokinetic properties for loperamide.

The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of loperamide have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of loperamide have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of loperamide have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2015-06-02

References

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson